Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfram Brugger

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Oncoimmunology|July 29, 2016
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapySusanne M Rittig, Maik Haentschel, Katrin J Weimer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2010
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patientsSusanne M Rittig, Maik Haentschel, Katrin J Weimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerLecia V Sequist, Joachim von Pawel, Edward G Garmey, et al.
Annals of Hematology|March 24, 2017
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemiaAnna Both, Jürgen Krauter, Frederik Damm, et al.
Leukemia & Lymphoma|August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitorPhilipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Annals of Neurology|February 9, 2002
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphomaUlrich Herrlinger, Martin Schabet, Wolfram Brugger, et al.
The Lancet. Oncology|December 15, 2015
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trialMathias Rummel, Ulrich Kaiser, Christina Balser, et al.
Haematologica|November 8, 2011
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyMichael Lübbert, Björn H Rüter, Rainer Claus, et al.
European Journal of Haematology|July 16, 2021
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myelomaChristian Straka, Hans Salwender, Stefan Knop, et al.
Blood|August 5, 2015
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Oncoimmunology|July 29, 2016
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapySusanne M Rittig, Maik Haentschel, Katrin J Weimer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2010
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patientsSusanne M Rittig, Maik Haentschel, Katrin J Weimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerLecia V Sequist, Joachim von Pawel, Edward G Garmey, et al.
Annals of Hematology|March 24, 2017
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemiaAnna Both, Jürgen Krauter, Frederik Damm, et al.
Leukemia & Lymphoma|August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitorPhilipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Annals of Neurology|February 9, 2002
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphomaUlrich Herrlinger, Martin Schabet, Wolfram Brugger, et al.
The Lancet. Oncology|December 15, 2015
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trialMathias Rummel, Ulrich Kaiser, Christina Balser, et al.
Haematologica|November 8, 2011
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyMichael Lübbert, Björn H Rüter, Rainer Claus, et al.
European Journal of Haematology|July 16, 2021
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myelomaChristian Straka, Hans Salwender, Stefan Knop, et al.
Blood|August 5, 2015
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.
Pageof 6